The Long Non-coding RNA BBOX1 Antisense RNA 1 is Upregulated in Polycystic Ovary Syndrome (PCOS) and Suppresses the Role of MicroRNA-19b in the Proliferation of Ovarian Granulose Cells : Short Title: BBOX1 Antisense RNA 1 in Cell Proliferation

Overview

Journal BMC Womens Health

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2023 Sep 22

PMID 37735639

Authors

Zhi Zhou

Yong Zhang

Can Tan

Juan Zhang

Guohui Yi

Bangbei Wang

Yejuan Li

Hui Lu

Weiying Lu

Xiaopo Zhang

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNA-19b (miR-19b) has been reported to be downregulated in polycystic ovary syndrome (PCOS), while its upstream regulators are unclear. We speculated that miR-19b could potentially form a binding relationship with BBOX1 antisense RNA 1 (BBOX1-AS1), a long non-coding RNA recognized for its critical role in ovarian cancer. Subsequently, we investigated into their interaction in PCOS.

Methods: The expression of miR-19b and BBOX1-AS1 in follicular fluid from both control women (n = 80) and women with PCOS (n = 80) was detected by RT-qPCR. Correlations were analyzed with Pearson' correlation coefficient. The binding of miR-19b to the wild-type (-wt) ad mutant (-mut) BBOX1-AS1 was determined by RNA-RNA pulldown assay. Their interactions were detected by overexpression assay. Bromodeoxyuridine (BrdU) assay was applied for proliferation analysis.

Results: BBOX1-AS1 was highly upregulated, while miR-19b was downregulated in PCOS. There was no close correlation across PCOS and the control samples. Consistently, they did not regulate the expression of each other in granulosa cells. However, BBOX1-AS1-wt, but not BBOX1-AS1-mut, could directly interact with miR-19b. BBOX1-AS1 suppressed the role of miR-19b in inhibiting granulosa cell proliferation.

Conclusion: BBOX1-AS1 is highly upregulated in PCOS, and it may serve as an endogenous competing RNA for miR-19b to suppress its role in inhibiting granulosa cell proliferation. Our study suggested the role of BBOX1-AS1 as a potential target to treat PCOS.

Citing Articles

Exosome Therapy and Photobiomodulation Therapy Regulate mi-RNA 21, 155 Expressions, Nucleus Acetylation and Glutathione in a Polycystic Ovary Oocyte: An In Vitro Study.

Sahraeian S, Abbaszadeh H, Taheripanah R, Edalatmanesh M, Keshavarzi S, Ghazifard A J Lasers Med Sci. 2024; 15:e10.

PMID: 39051004 PMC: 11267104. DOI: 10.34172/jlms.2024.10.

Whispers of the polycystic ovary syndrome theater: Directing role of long noncoding RNAs.

Lin X, Nie X, Deng P, Wang L, Hu C, Jin N Noncoding RNA Res. 2024; 9(4):1023-1032.

PMID: 39022674 PMC: 11254504. DOI: 10.1016/j.ncrna.2024.05.003.

References

Zhong Z, Li F, Li Y, Qin S, Wen C, Fu Y . Inhibition of microRNA-19b promotes ovarian granulosa cell proliferation by targeting IGF-1 in polycystic ovary syndrome. Mol Med Rep. 2018; 17(4):4889-4898. PMC: 5865948. DOI: 10.3892/mmr.2018.8463. View

Uppala J, Ghosh C, Sabat G, Dey M . Pull-down of Biotinylated RNA and Associated Proteins. Bio Protoc. 2022; 12(4):e4331. PMC: 8899547. DOI: 10.21769/BioProtoc.4331. View

Jiang M, Ni J, Cui W, Wang B, Zhuo W . Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019; 9(7):1354-1366. PMC: 6682721. View

Delkhosh A, Delashoub M, Tehrani A, Bahrami A, Niazi V, Shoorei H . Upregulation of FSHR and PCNA by administration of coenzyme Q10 on cyclophosphamide-induced premature ovarian failure in a mouse model. J Biochem Mol Toxicol. 2019; 33(11):e22398. DOI: 10.1002/jbt.22398. View

Dumitrescu R, Mehedintu C, Briceag I, Purcarea V, Hudita D . The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015; 8(2):142-5. PMC: 4392092. View

Moussa M, Perreau C, Baril G, Duchamp G, Vidament M, Daels P . Comparison of cell proliferation index in equine and caprine embryos using a modified BrdU incorporation assay. Theriogenology. 2005; 64(8):1823-32. DOI: 10.1016/j.theriogenology.2005.04.016. View

Walters K, Gilchrist R, Ledger W, Teede H, Handelsman D, Campbell R . New Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins. Trends Endocrinol Metab. 2018; 29(12):841-852. DOI: 10.1016/j.tem.2018.08.005. View

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

Barber T, Hanson P, Weickert M, Franks S . Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019; 13:1179558119874042. PMC: 6734597. DOI: 10.1177/1179558119874042. View

10.

Barthelmess E, Naz R . Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014; 6(1):104-19. PMC: 4341818. DOI: 10.2741/e695. View

11.

Mikaeili S, Hossein Rashidi B, Safa M, Najafi A, Sobhani A, Asadi E . Altered FoxO3 expression and apoptosis in granulosa cells of women with polycystic ovary syndrome. Arch Gynecol Obstet. 2016; 294(1):185-92. DOI: 10.1007/s00404-016-4068-z. View

12.

Li X, Zhu L, Luo Y . Long non-coding RNA HLA-F antisense RNA 1 inhibits the maturation of microRNA-613 in polycystic ovary syndrome to promote ovarian granulosa cell proliferation and inhibit cell apoptosis. Bioengineered. 2022; 13(5):12289-12297. PMC: 9275988. DOI: 10.1080/21655979.2022.2070965. View

13.

Abdalla M, Deshmukh H, Atkin S, Sathyapalan T . miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. Life Sci. 2020; 259:118174. DOI: 10.1016/j.lfs.2020.118174. View

14.

Risal S, Pei Y, Lu H, Manti M, Fornes R, Pui H . Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med. 2019; 25(12):1894-1904. DOI: 10.1038/s41591-019-0666-1. View

15.

Yao H, Chen R, Yang Y, Jiang J . LncRNA BBOX1-AS1 Aggravates the Development of Ovarian Cancer by Sequestering miR-361-3p to Augment PODXL Expression. Reprod Sci. 2020; 28(3):736-744. DOI: 10.1007/s43032-020-00366-5. View

16.

Yang R, Li Q, Zhou Z, Qian W, Zhang J, Wu Z . Changes in the prevalence of polycystic ovary syndrome in China over the past decade. Lancet Reg Health West Pac. 2022; 25:100494. PMC: 9162959. DOI: 10.1016/j.lanwpc.2022.100494. View

17.

Lauritsen M, Bentzen J, Pinborg A, Loft A, Forman J, Thuesen L . The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014; 29(4):791-801. DOI: 10.1093/humrep/det469. View

18.

Meier R . Polycystic Ovary Syndrome. Nurs Clin North Am. 2018; 53(3):407-420. DOI: 10.1016/j.cnur.2018.04.008. View

19.

George J, Kakkar R, Marshall J, Scott M, Finkelman R, Ho T . Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2016; 101(11):4313-4321. DOI: 10.1210/jc.2016-1202. View

20.

Riestenberg C, Jagasia A, Markovic D, Buyalos R, Azziz R . Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. J Clin Endocrinol Metab. 2021; 107(2):575-585. DOI: 10.1210/clinem/dgab613. View